Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166

Benzinga · 4d ago
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $160 to $166.